Tech-enabled contract research organization Vial announced last week it raised $67 million in Series B funding.
The round, which the startup said brings its total raise to more than $100 million, was led by General Catalyst with participation from Byers Capital, BoxGroup and other investors, per Mobi Health News.
Vial offers three technology platforms for running clinical trials: one for onboarding patients and launching the study, another for capturing data and outcomes, and a third geared toward recruiting trial participants.
